Log in to search using one of your social media accounts:

 

Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?

This article outlines the current and outstanding evidence for the use of multimodality treatment in this group of patients, including in combination with an increasing number of treatment options, such as immunotherapy and genotype-targeted small molecule inhibitors.Recent findingsOptimal therapy for surgically resectable stage III disease remains debatable and currently the choice of treatment reflects each individual patient ’s disease characteristics and the expertise and opinion of the thoracic multi-disciplinary team. Evidence for a distinct oligometastatic state in which improved outcomes can be achieved remains minimal and there is as yet no consensus definition for oligometastatic lung cancer. Whilst there is su pporting evidence for the aggressive management of isolated metastases, the use of consolidative therapy for multiple metastases remains unproven.SummaryEvolution of new RT technologies, improved surgical technique and a plethora of interventional-radiology-guided ablative therapies are widening the choice of available treatment modalities to patients with NSCLC. In the setting of resectable locally advanced disease and the oligometastatic state, there is a growing need for randomised comparison of the available treatment modalities to guide both treatment and patient selection.
Source: Current Surgery Reports - Category: Surgery Source Type: research

Related Links:

Authors: Re MD, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Maio MD, Petrini I, Danesi R Abstract Rationale: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not yet available. Nevertheless, many therapeutic approaches have been developed potentially useful to treat NSCLC patients mutated for KRAS and refractory to both standard chemotherapy and targeted therapies.The focus ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Immunotherapy,Volume 10, Issue 5, Page 403-410, April 2018.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
ConclusionsSimplified methodology to grade OS and weigh value of anticancer drugs was proposed. In 2nd-line non-squamous NSCLC, value of Doc, Nivo, Atezo and Pembro regardless of PDL-1 expression were limited and modest. Enrichment of PD-L1 resulted in unprecedented OS, improved grades and enhanced value at seemingly justifiable costs.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Opinion statementNext-generation sequencing (NGS) of circulating tumor DNA (ctDNA) is a novel technology that can complement tumor tissue NGS and has the potential to influence diagnosis and treatment of both localized and metastatic renal cell carcinoma (mRCC). ctDNA NGS is an attractive alternative to tumor tissue NGS because it circumvents the need for repeated, invasive tissue biopsies while providing a contemporary mutational profile of a patient ’s tumors. While the role of ctDNA NGS in non-small cell lung cancer and colorectal cancer is well established, studies of ctDNA NGS in mRCC are only hypothesis-generat...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
(Reuters) - The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the recent approval of new effective ...
Source: BMC Medicine - Category: Internal Medicine Authors: Tags: Commentary Source Type: research
AbstractPurpose of reviewStage IV non-small cell lung cancer (NSCLC) is a heterogenic disease with constant challenges for physicians. In the case of oligometastatic disease, surgery has a crucial role. In selected cases of a possible indolent progression of the malignancy, a surgical approach is recommended to control the disease. The management of this subset of patients should be performed in a multidisciplinary team in order to define the best strategy for each patient.Recent findingsThe implementation of optimizing surgical management has demonstrated better outcomes in terms of long-term survival with no detrimental ...
Source: Current Surgery Reports - Category: Surgery Source Type: research
Condition:   Carcinoma, Non-Small-Cell Lung Intervention:   Biological: Autologous Tcm cells immunotherapy Sponsors:   Beijing Friendship Hospital;   Newish Technology (Beijing) Co.,Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Radiology | Surgery